PolyPid PYPD 深 沪
已收盘 09-04 16:00:00 美东时间
5.39
+0.120
+2.28%
华盛通- 最 高5.44
- 今 开5.30
- 成交量 7.31万股
- 最 低 5.21
- 昨 收 5.27
- 总市值 1.09亿
- 52周最高 5.73
- 市盈率 静 --
- 换手率 0.36%
- 52周最低 3.06
- 委 比 -68.70%
- 总股本 2031.18万
- 历史最高 583.50
- 量 比 0.64
- 振 幅 4.36%
- 历史最低 2.30
- 每 手 1
- 风险率 0.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Analysts Are Bullish on These Healthcare Stocks: PolyPid (PYPD), Equillium (EQ)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-14 10:30
PolyPid (PYPD) 2026年第二季度业绩电话会议：D-PLEX100优先审评与Azurity交易
PolyPid 2026财年第二季度业绩电话会议涵盖了D-PLEX100优先审评、11月PDUFA日期、与Azurity的交易、净亏损收窄以及可支撑至2028年的现金储备。
08-14 08:35
PolyPid Q2 EPS $(0.35) Beats $(0.38) Estimate
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 55.13 percent increase over losses of $(0.78) per share from the same period last year.
08-12 19:30
PolyPid Announces FDA Acceptance Of Its New Drug Application With A Priority Review For D-PLEX100 For The Prevention Of Surgical Site Infections In Patients Undergoing Abdominal Colorectal Surgery; PDUFA Action Date Is November 28
The FDA did not identify any filing review issues and set a Prescription Drug User Fee Act ("PDUFA") target action date of November 28, 2026, approximately one quarter ahead of the Company’s previously communicated first quarter 2027 guidance. Priority Review shortens the FDA’s target review timelin...
07-29 20:34
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
PolyPid Signs Agreement With Azurity Pharmaceuticals To Commercialize D-PLEX100 In U.S., Canada To Prevent Surgical Site Infections; PolyPid To Receive $15M Upfront Payment
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins, today announced that it has entered into an exclusive commercial partnership agreement (the "Agreement") with Azurity Pharmaceutic...
07-21 19:32
PolyPid Completes Its New Drug Application Submission On Rolling Review Basis Top FDA For D-PLEX100 To Prevent Surgical Site Infections
PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced the
06-01 20:40
PolyPid Q1 2026 Earnings Call: Complete Transcript
PolyPid (NASDAQ:PYPD) held its first-quarter earnings conference call on Wednes...
05-13 21:24
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
PolyPid Ltd. (Nasdaq: PYPD) announced it will report its first quarter 2026 financial results and operational highlights on Wednesday, May 13, 2026, before the U.S. market open. A conference call and webcast at 8:30 AM Eastern Time will discuss the results and business updates. The company, focused on improving patient outcomes through innovative biopharmaceuticals, invites participants to register in advance for the call or listen via webcast.
05-06 12:00
